Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 501 to 525 of 890

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)	TA625	4 March 2020	4 March 2020
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis	TA624	19 February 2020	19 February 2020
Patiromer for treating hyperkalaemia	TA623	13 February 2020	13 February 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)	TA618	15 January 2020	15 January 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	TA617	8 January 2020	8 January 2020
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome	TA614	18 December 2019	18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome	TA615	18 December 2019	18 December 2019
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	TA612	20 November 2019	20 November 2019
Pentosan polysulfate sodium for treating bladder pain syndrome	TA610	13 November 2019	13 November 2019
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)	TA608	30 October 2019	30 October 2019
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)	TA609	30 October 2019	30 October 2019
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	TA607	17 October 2019	17 October 2019
Lanadelumab for preventing recurrent attacks of hereditary angioedema	TA606	16 October 2019	16 October 2019
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea	TA605	9 October 2019	9 October 2019
Idelalisib for treating refractory follicular lymphoma	TA604	2 October 2019	2 October 2019
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA602	25 September 2019	25 September 2019
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)	TA603	25 September 2019	25 September 2019
Benralizumab for treating severe eosinophilic asthma	TA565	6 March 2019	3 September 2019
Risankizumab for treating moderate to severe plaque psoriasis	TA596	21 August 2019	21 August 2019
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer	TA595	14 August 2019	14 August 2019
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis	TA590	31 July 2019	31 July 2019
Letermovir for preventing cytomegalovirus disease after a stem cell transplant	TA591	31 July 2019	31 July 2019
Nusinersen for treating spinal muscular atrophy	TA588	24 July 2019	24 July 2019
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	TA589	24 July 2019	24 July 2019
Bisphosphonates for treating osteoporosis	TA464	9 August 2017	8 July 2019

Results per page

10
25
50
All